Drug Profile
Interferon beta-1b biosimilar - Proteos biotech
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Proteos biotech
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 06 Jul 2015 Discontinued for Multiple sclerosis in Spain (SC) (Proteos biotech pipeline, July 2015)
- 05 Jun 2015 Early research in Multiple sclerosis in Spain (SC) (Proteos biotech product pipeline, June 2015)